Company: IOBT
Filing Date: 2025-05-23
Form Type: S-3
Source: 0001193125-25-125831
Chunk: 20

Company: IO Biotech, Inc.
Filing Date: 2025-05-23
Form: S-3
Chunk 20
---
 accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.

We have agreed to keep this prospectus effective until the earliest to occur of the following events after the date in which the Tranche A Warrants, Tranche B
Warrants and the Tranche C Warrants have been issued pursuant to the Warrant Issuance Agreement or such earlier date on which the Company has no outstanding obligation to issue Warrants under the Warrant Issuance Agreement: (i) the date on
which the selling stockholders shall have resold all the Shares covered hereby; and iii) the date on which the Shares may be resold or transferred by the selling stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information requirement under Rule 144
under the Securities Act or any other rule of similar effect, and new

14

certificates for such securities not bearing a legend restricting further transfer have been issued to the selling stockholders. In order to comply with the securities laws of some states, if
applicable, the shares of our common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the shares of our common stock may not be sold unless the shares been registered or
qualified for sale or an exemption from registration or qualification requirements is available and is complied with.

The selling stockholders and any
other person participating in a sale of shares of our common stock registered under this prospectus will be subject to applicable provisions of the Exchange Act, and the rules and regulations thereunder, including, without limitation, to the extent
applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of our common stock by the selling stockholders and any other participating person. All of the foregoing may affect the
marketability of the shares of our common stock and the ability of any person or entity to engage in market-making activities with respect to the shares of our common stock. In addition, we will make copies of this prospectus (as it may be
supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in
transactions involving the sale of the shares of our common stock against certain liabilities,